Table 6.
Reasons for discontinuation of bisphosphonates in patients with bone metastases/lesions, by malignancy type and by country: data from the detailed questionnaire
| Response given (%) | Total (N = 1838) | France (n = 392) | Germany (n = 516) | Italy (n = 363) | Spain (n = 309) | UK (n = 258) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | |
| End of treatment as planneda | 51 | 72 | 48 | 77 | 67 | 60 | 38 | 68 | 44 | 85 | 36 | 56 |
| Toxicity | 16 | 11 | 25 | 7 | 7 | 18 | 20 | 15 | 34 | 9 | 3 | 5 |
| Risk of toxicity | 7 | 6 | 10 | 3 | 9 | 17 | 5 | 9 | 5 | 1 | 6 | 9 |
| Lack of efficacyb | 12 | 4 | 7 | 7 | 13 | 9 | 20 | 1 | 7 | 1 | 10 | 3 |
| Contraindication due to concomitant treatment | 3 | 1 | 1 | 1 | 3 | 8 | 0 | 0 | 3 | 1 | 1 | 0 |
| Other | 9 | 7 | 18 | 11 | 4 | 10 | 16 | 6 | 5 | 0 | 7 | 8 |
Investigators could give more than one response.
HM, haematological malignancy; ST, solid tumour.
a
Planned duration of treatment was determined by treating physician.
b
As determined by treating physician.